Deciphering multiple sclerosis disability with deep learning attention maps on clinical MRI
- PMID: 36940621
- PMCID: PMC10034138
- DOI: 10.1016/j.nicl.2023.103376
Deciphering multiple sclerosis disability with deep learning attention maps on clinical MRI
Abstract
The application of convolutional neural networks (CNNs) to MRI data has emerged as a promising approach to achieving unprecedented levels of accuracy when predicting the course of neurological conditions, including multiple sclerosis, by means of extracting image features not detectable through conventional methods. Additionally, the study of CNN-derived attention maps, which indicate the most relevant anatomical features for CNN-based decisions, has the potential to uncover key disease mechanisms leading to disability accumulation. From a cohort of patients prospectively followed up after a first demyelinating attack, we selected those with T1-weighted and T2-FLAIR brain MRI sequences available for image analysis and a clinical assessment performed within the following six months (N = 319). Patients were divided into two groups according to expanded disability status scale (EDSS) score: ≥3.0 and < 3.0. A 3D-CNN model predicted the class using whole-brain MRI scans as input. A comparison with a logistic regression (LR) model using volumetric measurements as explanatory variables and a validation of the CNN model on an independent dataset with similar characteristics (N = 440) were also performed. The layer-wise relevance propagation method was used to obtain individual attention maps. The CNN model achieved a mean accuracy of 79% and proved to be superior to the equivalent LR-model (77%). Additionally, the model was successfully validated in the independent external cohort without any re-training (accuracy = 71%). Attention-map analyses revealed the predominant role of frontotemporal cortex and cerebellum for CNN decisions, suggesting that the mechanisms leading to disability accrual exceed the mere presence of brain lesions or atrophy and probably involve how damage is distributed in the central nervous system.
Keywords: Attention maps; Deep learning; Disability; Multiple sclerosis; Structural MRI.
Copyright © 2023. Published by Elsevier Inc.
Conflict of interest statement
Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Ll. Coll: nothing to disclose. D. Pareto: has received a research contract with Biogen Idec, and a grant from Instituto Salud Carlos III (PI18/00823). P. Carbonell-Mirabent: his yearly salary is supported by a grant from Biogen to Fundació privada Cemcat for statistical analysis. A. Cobo-Calvo: has received grant from Instituto de Salud Carlos III, Spain; JR19/00007. G. Arrambide: has received compensation for consulting services, participation in advisory boards or speaking honoraria from Merck, Roche, and Horizon Therapeutics; and travel support for scientific meetings from Novartis, Roche, and ECTRIMS. G. Arrambide is editor for Europe of the Multiple Sclerosis Journal – Experimental, Translational and Clinical; a member of the executive committee of the International Women in Multiple Sclerosis (iWiMS) network, and a member of the European Biomarkers in MS (BioMS-eu) consortium steering committee. She is a recipient of grants PI19/01590 and PI22/01570, awarded by the Instituto de Salud Carlos III (ISCIII), Ministerio de Ciencia e Innovación de España. Á. Vidal Jordana: has engaged in consulting and/or participated as speaker in events organized by Roche, Novartis, Merck, and Sanofi. M. Comabella: has received compensation for consulting services and speaking honoraria from Bayer Schering Pharma, Merk Serono, Biogen-Idec, Teva Pharmaceuticals, Sanofi-Aventis, and Novartis. J. Castilló: nothing to disclose. B. Rodríguez-Acevedo: has received honoraria for consulting services from Wellspect. A. Zabalza: nothing to disclose. I. Galán: nothing to disclose. L. Midaglia: nothing to disclose. C. Nos: has received funding for travel from Biogen Idec and F. Hoffmann-La Roche, Ltd. and speaker honoraria from Novartis. A. Salerno: nothing to disclose. C. Auger: has received speaking honoraria from Novartis, Biogen and Stendhal. M. Alberich: nothing to disclose. J. Río: has received speaking honoraria and personal compensation for participating on Advisory Boards from Biogen-Idec, Genzyme, Merck- Serono, Mylan, Novartis, Roche, Teva, and Sanofi-Aventis. J. Sastre-Garriga: serves as co-Editor for Europe on the editorial board of Multiple Sclerosis Journal and as Editor-in-Chief in Revista de Neurología, receives research support from Fondo de Investigaciones Sanitarias (19/950) and has served as a consultant/speaker for Biogen, Celgene/Bristol Meyers Squibb, Genzyme, Novartis and Merck. A. Oliver: nothing to disclose. X. Montalban: has received speaking honoraria and travel expenses for participation in scientific meetings, has been a steering committee member of clinical trials or participated in advisory boards of clinical trials in the past years with Abbvie, Actelion, Alexion, Biogen, Bristol-Myers Squibb/Celgene, EMD Serono, Genzyme, Hoffmann-La Roche, Immunic, Janssen Pharmaceuticals, Medday, Merck, Mylan, Nervgen, Novartis, Sandoz, Sanofi-Genzyme, Teva Pharmaceutical, TG Therapeutics, Excemed, MSIF and NMSS. A. Rovira: serves on scientific advisory boards for Novartis, Sanofi-Genzyme, Synthetic MR, Roche, Biogen, and OLEA Medical; has received speaker honoraria from Bayer, SanofiGenzyme, Merck-Serono, Teva Pharmaceutical Industries Ltd, Novartis, Roche, and Biogen; and is CMO and co-founder of TensorMedical. M. Tintoré: has received compensation for consulting services and speaking honoraria from Almirall, Bayer Schering Pharma, Biogen-Idec, Genzyme, Merck-Serono, Novartis, Roche, Sanofi-Aventis, and Teva Pharmaceuticals. MT is former co-editor of Multiple Sclerosis Journal. X. Lladó: is currently being supported by the ICREA Academia Program. He has also received support from the DPI2020-114769RBI00 project funded by the Ministerio de Ciencia, Innovación y Universidades. C. Tur: is currently being funded by a Junior Leader La Caixa Fellowship (fellowship code is LCF/BQ/PI20/11760008), awarded by “la Caixa” Foundation (ID 100010434). She has also received the 2021 Merck’s Award for the Investigation in MS, awarded by Fundación Merck Salud (Spain) and a grant awarded by the Instituto de Salud Carlos III (ISCIII), Ministerio de Ciencia e Innovación de España (PI21/01860). In 2015, she received an ECTRIMS Post-doctoral Research Fellowship and has received funding from the UK MS Society. She is a member of the Editorial Board of Neurology. She has also received honoraria from Roche and Novartis and is a steering committee member of the O’HAND trial and of the Consensus group on Follow-on DMTs.
Figures





References
-
- Amato M.P., Portaccio E., Stromillo M.L., Goretti B., Zipoli V., Siracusa G., Battaglini M., Giorgio A., Bartolozzi M.L., Guidi L., Sorbi S., Federico A., de Stefano N. Cognitive assessment and quantitative magnetic resonance metrics can help to identify benign multiple sclerosis. Neurology. 2008;71(9):632–638. doi: 10.1212/01.wnl.0000324621.58447.00. - DOI - PubMed
-
- Bove R., Poole S., Cuneo R., Gupta S., Sabatino J., Harms M., Cooper T., Rowles W., Miller N., Gomez R., Lincoln R., McPolin K., Powers K., Santaniello A., Renschen A., Bevan C.J., Gelfand J.M., Goodin D.S., Guo C.-Y., Romeo A.R., Hauser S.L., Campbell Cree B.A. Remote observational research for multiple sclerosis: a natural experiment. Neurology(R) Neuroimmunol. Neuroinflamm. 2023;10(2):e200070. - PMC - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical